Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
608 hedge funds and large institutions have $20.4B invested in Alexion Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 101 funds opening new positions, 200 increasing their positions, 234 reducing their positions, and 72 closing their positions.
40% more first-time investments, than exits
New positions opened: 101 | Existing positions closed: 72
4% more funds holding
Funds holding: 584 → 608 (+24)
9% less call options, than puts
Call options by funds: $184M | Put options by funds: $201M
15% less repeat investments, than reductions
Existing positions increased: 200 | Existing positions reduced: 234
31% less capital invested
Capital invested by funds: $29.5B → $20.4B (-$9.09B)
56% less funds holding in top 10
Funds holding in top 10: 18 → 8 (-10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$627M |
| 2 |
JP Morgan Chase
New York
|
+$93.6M |
| 3 |
Millennium Management
New York
|
+$77.8M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$70.9M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$53.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$378M |
| 2 |
Bessemer Group
Woodbridge,
New Jersey
|
-$131M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$130M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$107M |
| 5 |
O
OrbiMed
New York
|
-$98.5M |
ALXN Hedge Fund Activity: Q4 2018 in Review
608 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q4 2018, worth a combined $20.4B — down 31% from $29.5B a quarter earlier.
Buyers outnumbered sellers: 101 funds opened new ALXN positions and 72 closed out — a net gain of 29 holders — while 200 added to existing stakes and 234 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $627M. The largest seller was T. Rowe Price Associates, cutting an estimated $378M.
- 608 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q4 2018, up from 584 in Q3 2018.
- Funds reported $20.4B of Alexion Pharmaceuticals stock for Q4 2018, down 31% quarter-over-quarter.
- 101 funds opened new Alexion Pharmaceuticals positions in Q4 2018 and 72 closed out, a net change of +29 holders.
- The largest Alexion Pharmaceuticals buyer in Q4 2018 was Fidelity Investments, an estimated $627M added.
- The largest Alexion Pharmaceuticals seller in Q4 2018 was T. Rowe Price Associates, an estimated $378M sold.
Based on aggregated 13F filings for Q4 2018.